{"id":4212,"date":"2026-11-05T09:00:00","date_gmt":"2026-11-05T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4212"},"modified":"2026-11-11T20:45:24","modified_gmt":"2026-11-12T00:45:24","slug":"cd20-car-t-shows-responses-in-ten-heavily-treated-wm-patients","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4212","title":{"rendered":"CD20 CAR T Shows Responses in Ten Heavily Treated WM Patients"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Blood_CD20_CAR_T_WM_Therapeutic_Indications-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4239\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Blood_CD20_CAR_T_WM_Therapeutic_Indications-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Blood_CD20_CAR_T_WM_Therapeutic_Indications-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Blood_CD20_CAR_T_WM_Therapeutic_Indications-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Blood_CD20_CAR_T_WM_Therapeutic_Indications.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Fred Hutchinson Cancer Center (academic)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (Blood)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Autologous CAR T<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>CD20-directed CAR T<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD20<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Waldenstr\u00f6m macroglobulinemia<\/p>\n<h4>Summary<\/h4>\n<p>Source-gap recovery: a peer-reviewed Blood letter published online November 5, 2026 reported CD20-directed autologous CAR-T in ten patients with Waldenstr\u00f6m macroglobulinemia (WM) progressing after a BTK inhibitor. The reported complete or very good partial response rate was 80%; this uncontrolled small study cannot establish comparative efficacy.<\/p>\n<p>All ten screened patients were treated and analyzed. The median prior lines of therapy were 9.5. The journal abstract reports 80% complete or very good partial response. The trial is registered as NCT03277729. The online-first date is November 5; the paper was recovered through the 14-day publication reconciliation, with no new November 11 clinical readout implied.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>WM is a lymphoplasmacytic B-cell malignancy with a small but difficult post-BTK-inhibitor population. <strong>Interpretation A:<\/strong> CD20 CAR-T can produce deep responses despite extensive previous anti-CD20 exposure. Supporting evidence is the 80% deep-response proportion in ten BTKi-progressing patients, nine of whom had prior anti-CD20 antibody treatment. Against: target expression at infusion, response duration, and selection effects need scrutiny, and prior anti-CD20 therapy may have occurred years earlier.<\/p>\n<p><strong>Interpretation B:<\/strong> the striking result may overestimate a repeatable benefit in broader WM because of small sample size, single-arm design, specialized manufacturing and supportive care. Support: the cohort is ten, and a few outcome changes would materially alter the rate. Against: very heavy pretreatment makes the signal clinically meaningful. Independent multicenter cohorts, longer progression-free survival, standardized response adjudication, CD20 antigen tracking, CAR persistence, cytokine-release and neurotoxicity details, infections and cytopenias are decisive. The cell-collection and production pathway also determines access and scalability.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Waldenstr\u00f6m macroglobulinemia is an IgM-producing lymphoplasmacytic lymphoma. Autologous CD20 CAR-T is manufactured from a patient\u2019s T cells and redirects them against CD20-positive malignant and normal B cells. The study is academic, with investigators at Fred Hutchinson Cancer Center; it is not a marketed WM product.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified: peer-reviewed online-first publication, N=10, BTKi progression, 80% complete or very good partial response, registered study.<\/li>\n<li>Independent corroboration: Blood first-edition index and PubMed.<\/li>\n<li>Missing: comparator, mature durability, complete safety granularity and manufacturing success across centers.<\/li>\n<li>Falsifier: materially lower deep-response or unacceptable toxicity in a larger consecutive cohort.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The paper places a deep clinical-response signal into a setting without an approved CAR-T option. The immediate translational question is whether durability and safety survive larger, less selected testing.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: high for publication, cohort size and abstract response rate; moderate for detailed efficacy and safety without full dataset appraisal. Confidence in Interpretation: low to moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Source-gap recovery: a peer-reviewed Blood letter published online November 5, 2026 reported CD20-directed autologous CAR-T in ten patients with Waldenstr\u00f6m macroglobulinemia (WM) progressing after a BTK inhibitor. The reported complete or very good partial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4239,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1435,1434,1436],"class_list":["post-4212","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-cd20-car-t","tag-fred-hutchinson-cancer-center","tag-waldenstrom-macroglobulinemia"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4212"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4212\/revisions"}],"predecessor-version":[{"id":4245,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4212\/revisions\/4245"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4239"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}